We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cronos Group (CRON) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
In the latest trading session, Cronos Group (CRON - Free Report) closed at $9.70, marking a -0.82% move from the previous day. This move lagged the S&P 500's daily loss of 0.04%. Elsewhere, the Dow gained 0.15%, while the tech-heavy Nasdaq lost 0.67%.
Coming into today, shares of the cannabis company had lost 15.92% in the past month. In that same time, the Finance sector lost 1.11%, while the S&P 500 gained 0.02%.
Wall Street will be looking for positivity from CRON as it approaches its next earnings report date. This is expected to be November 26, 2018. In that report, analysts expect CRON to post earnings of $0.01 per share. This would mark no growth from the year-ago period. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.29 million, up 975.24% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.02 per share and revenue of $23.87 million, which would represent changes of -300% and +649.69%, respectively, from the prior year.
Any recent changes to analyst estimates for CRON should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. CRON currently has a Zacks Rank of #3 (Hold).
The Financial - Investment Management industry is part of the Finance sector. This industry currently has a Zacks Industry Rank of 72, which puts it in the top 28% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cronos Group (CRON) Dips More Than Broader Markets: What You Should Know
In the latest trading session, Cronos Group (CRON - Free Report) closed at $9.70, marking a -0.82% move from the previous day. This move lagged the S&P 500's daily loss of 0.04%. Elsewhere, the Dow gained 0.15%, while the tech-heavy Nasdaq lost 0.67%.
Coming into today, shares of the cannabis company had lost 15.92% in the past month. In that same time, the Finance sector lost 1.11%, while the S&P 500 gained 0.02%.
Wall Street will be looking for positivity from CRON as it approaches its next earnings report date. This is expected to be November 26, 2018. In that report, analysts expect CRON to post earnings of $0.01 per share. This would mark no growth from the year-ago period. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.29 million, up 975.24% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.02 per share and revenue of $23.87 million, which would represent changes of -300% and +649.69%, respectively, from the prior year.
Any recent changes to analyst estimates for CRON should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. CRON currently has a Zacks Rank of #3 (Hold).
The Financial - Investment Management industry is part of the Finance sector. This industry currently has a Zacks Industry Rank of 72, which puts it in the top 28% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.